Amylyx Pharmaceuticals, Inc. (AMLX) vs Parabilis Medicines, Inc. (PBLS)

A side-by-side comparison of Amylyx Pharmaceuticals, Inc. and Parabilis Medicines, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Amylyx Pharmaceuticals, Inc. logo
AMLX
Amylyx Pharmaceuticals, Inc.
$3.12B
$28.04HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Parabilis Medicines, Inc. logo
PBLS
Parabilis Medicines, Inc.
$3.36B
$28.86HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — AMLX vs PBLS

growth of $100 · dividends reinvested · last 1y
AMLX +113.5% (+113.5%/yr)PBLS +47.7% (+47.7%/yr)AMLX compounded faster over this window
100150200250300Start $100$214$148
AMLX PBLS

AMLX vs PBLS: by the numbers

  • •PBLS is the larger company ($3.36B vs $3.12B market cap).

Metrics side by side

Valuation

MetricAMLXPBLS
P/B ratio13.043.21

Profitability

MetricAMLXPBLS
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-63.59%N/A
ROIC-66.60%-409.85%

Go deeper

Full AMLX analysisFull PBLS analysisInteractive comparison tool

Dig into the metrics

Amylyx Pharmaceuticals ROEParabilis Medicines ROEAmylyx Pharmaceuticals operating marginParabilis Medicines operating marginAmylyx Pharmaceuticals revenue growthParabilis Medicines revenue growthAmylyx Pharmaceuticals free cash flowParabilis Medicines free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.